Tres Alchemix, a pioneering biotechnology company specializing in artificial intelligence (AI) drug discovery, has announced the successful closure of a $4.4 million [¥650 million] Series A financing round. The investment was led by DNX Ventures, with support from existing investor Waseda University Ventures.
According to Tres Alchemix, the funds will be utilized to accelerate the development of their predictive AI platform and to establish a new laboratory at The Oxford Science Park, a renowned hub for cutting-edge science and technology companies. This expansion will also support Tres Alchemix’s research and development efforts in the United Kingdom.
Founded in 2023 by three accomplished DPhil (PhD) graduates from the University of Oxford, Tres Alchemix is dedicated to revolutionizing drug discovery through advanced technologies that integrate multi-omic and multimodal big data with proprietary quantum-chemical calculation methods. This unique approach allows the company to create predictive models of biological and biochemical processes in the human body, accurately forecasting the therapeutic effects and potential side effects of new drugs. By leveraging this technology, Tres Alchemix aims to design novel small-molecule candidates that maximize efficacy while minimizing risk.
While headquartered in Fukuoka, Japan, Tres Alchemix has also established a research and development subsidiary in Oxford in 2024. With the additional funding, the company aims to further strengthen its regional operations and focus on developing new treatments for oncology.
Tres Alchemix’s Co-founder and CEO, Hisashi Hashimoto, expressed his confidence in the company’s technology, stating, “We believe our technology can be a game changer for the drug-discovery field. Our models can accurately predict drug effects and potential side effects and can even propose new compounds tailored to disease biology.” He added that this capability allows the company to expedite the hit-discovery phase and reduce the risk of late-stage clinical failure.
DNX Ventures, the lead investor in Tres Alchemix’s Series A round, shared their enthusiasm for the company’s innovative approach. “DNX is excited to lead the investment in Tres Alchemix and their human in silico models, which simulate drug behaviour in the body and enable high-precision predictions of both therapeutic effects and potential risks,” said Akira Kurabayashi, Managing Partner and Head of Japan at DNX Ventures.
Yoshiki Shiraishi, Partner at DNX Ventures, further added, “The three co-founders, who met at the University of Oxford, bring together expertise in medicine, computer science, and quantum chemical calculations. We believe that the innovative methodology developed by these three (“Tres”) scientists will play a leading role in transforming global drug development.”
About Tres Alchemix
Tres Alchemix is a biotechnology company that leverages artificial intelligence to develop a predictive drug-design platform for creating next-generation small-molecule therapies. By combining multi-omic and multimodal datasets with proprietary quantum-chemical calculation methods, the company has built a human in silico model capable of forecasting the efficacy and safety of novel compounds. Founded in 2023 in Fukuoka, Japan, Tres Alchemix is expanding its operations in the United Kingdom with a new laboratory at The Oxford Science Park.
This news story was originally distributed by https://pressat.co.uk/.
